Impact of a community-based naloxone distribution program on opioid overdose death rates.
Harm reduction
Naloxone
Narcotic
Opioid
Overdose
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
08
02
2019
revised:
25
06
2019
accepted:
27
06
2019
pubmed:
9
9
2019
medline:
28
7
2020
entrez:
9
9
2019
Statut:
ppublish
Résumé
In August 2013, a naloxone distribution program was implemented in North Carolina (NC). This study evaluated that program by quantifying the association between the program and county-level opioid overdose death (OOD) rates and conducting a cost-benefit analysis. One-group pre-post design. Data included annual county-level counts of naloxone kits distributed from 2013 to 2016 and mortality data from 2000-2016. We used generalized estimating equations to estimate the association between cumulative rates of naloxone kits distributed and annual OOD rates. Costs included naloxone kit purchases and distribution costs; benefits were quantified as OODs avoided and monetized using a conservative value of a life. The rate of OOD in counties with 1-100 cumulative naloxone kits distributed per 100,000 population was 0.90 times (95% CI: 0.78, 1.04) that of counties that had not received kits. In counties that received >100 cumulative kits per 100,000 population, the OOD rate was 0.88 times (95% CI: 0.76, 1.02) that of counties that had not received kits. By December 2016, an estimated 352 NC deaths were avoided by naloxone distribution (95% CI: 189, 580). On average, for every dollar spent on the program, there was $2742 of benefit due to OODs avoided (95% CI: $1,237, $4882). Our estimates suggest that community-based naloxone distribution is associated with lower OOD rates. The program generated substantial societal benefits due to averted OODs. States and communities should continue to support efforts to increase naloxone access, which may include reducing legal, financial, and normative barriers.
Sections du résumé
BACKGROUND
In August 2013, a naloxone distribution program was implemented in North Carolina (NC). This study evaluated that program by quantifying the association between the program and county-level opioid overdose death (OOD) rates and conducting a cost-benefit analysis.
METHODS
One-group pre-post design. Data included annual county-level counts of naloxone kits distributed from 2013 to 2016 and mortality data from 2000-2016. We used generalized estimating equations to estimate the association between cumulative rates of naloxone kits distributed and annual OOD rates. Costs included naloxone kit purchases and distribution costs; benefits were quantified as OODs avoided and monetized using a conservative value of a life.
RESULTS
The rate of OOD in counties with 1-100 cumulative naloxone kits distributed per 100,000 population was 0.90 times (95% CI: 0.78, 1.04) that of counties that had not received kits. In counties that received >100 cumulative kits per 100,000 population, the OOD rate was 0.88 times (95% CI: 0.76, 1.02) that of counties that had not received kits. By December 2016, an estimated 352 NC deaths were avoided by naloxone distribution (95% CI: 189, 580). On average, for every dollar spent on the program, there was $2742 of benefit due to OODs avoided (95% CI: $1,237, $4882).
CONCLUSIONS
Our estimates suggest that community-based naloxone distribution is associated with lower OOD rates. The program generated substantial societal benefits due to averted OODs. States and communities should continue to support efforts to increase naloxone access, which may include reducing legal, financial, and normative barriers.
Identifiants
pubmed: 31494440
pii: S0376-8716(19)30295-9
doi: 10.1016/j.drugalcdep.2019.06.038
pmc: PMC8107918
mid: NIHMS1695176
pii:
doi:
Substances chimiques
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
107536Subventions
Organisme : NCIPC CDC HHS
ID : R49 CE001495
Pays : United States
Organisme : NCIPC CDC HHS
ID : U17 CE002728
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Am J Public Health. 2009 May;99(5):788-91
pubmed: 19363214
Addiction. 2008 Oct;103(10):1648-57
pubmed: 18821875
J Psychoactive Drugs. 2018 Jul-Aug;50(3):240-246
pubmed: 29424656
Subst Use Misuse. 2008;43(7):858-70
pubmed: 18570021
Addiction. 2008 Jun;103(6):979-89
pubmed: 18422830
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
Addict Behav. 2006 May;31(5):907-12
pubmed: 16139434
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631-5
pubmed: 26086633
Drugs (Abingdon Engl). 2015 Feb;22(1):66-76
pubmed: 26045638
Am J Public Health. 2009 Mar;99(3):402-7
pubmed: 19150908
Int J Drug Policy. 2010 May;21(3):186-93
pubmed: 19268564
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Int J Drug Policy. 2009 Mar;20(2):131-6
pubmed: 18434126
N Engl J Med. 2016 Dec 8;375(23):2213-2215
pubmed: 27959694
Harm Reduct J. 2009 Sep 25;6:26
pubmed: 19781073
Addiction. 2017 Feb;112(2):301-308
pubmed: 27614084
Addiction. 2014 Feb;109(2):250-9
pubmed: 24103087
Annu Rev Public Health. 1995;16:61-81
pubmed: 7639884
Ann Intern Med. 2013 Jan 1;158(1):1-9
pubmed: 23277895
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807